WALTHAM, MA (October 2, 2014): NKT Therapeutics, Inc., a privately held biotechnology company, announced Fast Track designation for NKTT120 in sickle cell disease, and completion of dosing in its Phase 1b trial.
WALTHAM, MA (April 14, 2014): NKT Therapeutics, Inc., a privately held biotechnology company, presented data on its novel platform for electronic data collection in clinical trials in patients with sickle cell disease at the Annual Research Meeting of the Foundation for Sickle Cell Disease Research.
WALTHAM, MA (April 6, 2014): NKT Therapeutics, Inc., a privately held biotechnology company, presented preclinical data on NKTT320, a humanized monoclonal antibody for the treatment of cancer and autoimmune disease at the annual meeting of the American Association of Cancer Research
WALTHAM, MA (December 10, 2013): NKT Therapeutics, Inc., a privately held biotechnology company, presented interim data on its Phase 1b clinical trial of NKTT120 in patients with sickle cell disease and its discovery of antibodies specific for the murine invariant T cell receptor (iTCR) at the Annual Meeting of the American Society of Hematology.
WALTHAM, MA (April 16, 2013):
NKT Therapeutics, Inc., a privately held biotechnology company, had three presentations at the National Sickle Cell Disease Scientific Meeting regarding its Phase 1b Study of NKTT120 in Adults with Sickle Cell Disease
WALTHAM, MA (December 8, 2012):
NKT Therapeutics, Inc., a privately held biotechnology company, announced preclinical study results supporting the potential of its lead therapeutic candidate, NKTT120, as an innovative approach to the treatment of sickle cell disease.
PRINCETON, NJ AND WALTHAM, MA (October 21, 2009):
BioWa, Inc. (BioWa) and NKT Therapeutics, Inc. (NKTT), announced today that they
have entered into an agreement which provides NKTT with access to BioWa’s patented
POTELLIGENT® Technology platform for the development of antibody-dependent cellular
cytotoxicity (ADCC) enhanced antibodies.
GENEVA, SWITZERLAND (September 1, 2009):
Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today that they have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M™. The Selexis INTEGRAD2M™ platform enables the rapid isolation of production cell lines concomitant with the selection of lead compounds from libraries of protein variants expressed in Chinese Hamster Ovary (CHO) cells. Utilizing INTEGRA-D2M™, protein variant libraries of sizes larger than 103 can be screened to identify lead compounds in less than 9 weeks. The selected CHO-based protein variant expressing clone can then be used directly for cGMP manufacturing.
WALTHAM, MA (July 27, 2009):
NKT Therapeutics Broadens Scientific Advisory Board with Three New Appointments NEWTON, MA (July 27, 2009): NKT Therapeutics, Inc., a privately held biotechnology company, today announced three new appointments to the company’s scientific advisory board (SAB). The additions include:
• Peter Cresswell, Ph.D., Professor of Immunobiology, Cell Biology and Dermatology at Yale University School of Medicine
• Peter A. Kiener, D. Phil., Executive Vice President, Research & Development at MedImmune.
• David Wofsy, M.D., Professor of Medicine and Microbiology/Immunology at the University of California, San Francisco